Quantity of eligible individuals: CDEC talked about the uncertainty in the amount of sufferers with moderately severe to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some patients who will be categorized as having mild or reasonable ailment could have a extreme bleeding ph